Differential display screening was used to reveal differential gene expression between the tumorigenic breast cancer cell line CAL51 and nontumorigenic microcell hybrids obtained after transfer of human chromosome 17 into CAL51. The human profilin 1 (PFN1) gene was found overexpressed in the microcell hybrid clones compared with the parental line, which displayed a low profilin 1 level. A comparison between several different tumorigenic breast cancer cell lines with nontumorigenic lines showed consistently lower profilin 1 levels in the tumor cells. Transfection of PFN1 cDNA into CAL51 cells raised the profilin 1 level, had a prominent effect on cell growth, cytoskeletal organization and spreading, and suppressed tumorigenicity of the stable, PFN1-overexpressing cell clones in nude mice. Immunohistochemical analysis revealed intermediate and low levels of profilin 1 in different human breast cancers. These results suggest profilin 1 as a suppressor of the tumorigenic phenotype of breast cancer cells.
Skip Nav Destination
Article navigation
15 May 2000
Article|
May 08 2000
Suppression of Tumorigenicity in Breast Cancer Cells by the Microfilament Protein Profilin 1
Jürgen Janke,
Jürgen Janke
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Kathrin Schlüter,
Kathrin Schlüter
bDepartment of Cell Biology, Zoological Institute, Technical University of Braunschweig, 38106 Braunschweig, Germany
Search for other works by this author on:
Burkhard Jandrig,
Burkhard Jandrig
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Michael Theile,
Michael Theile
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Konrad Kölble,
Konrad Kölble
cInstitute of Pathology, Charité Hospital, Humboldt University, 10117 Berlin, Germany
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Search for other works by this author on:
Wolfgang Arnold,
Wolfgang Arnold
dHepaVec GmbH, 13125 Berlin-Buch, Germany
Search for other works by this author on:
Edgar Grinstein,
Edgar Grinstein
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Arnfried Schwartz,
Arnfried Schwartz
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Lope Estevéz-Schwarz,
Lope Estevéz-Schwarz
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Search for other works by this author on:
Peter M. Schlag,
Peter M. Schlag
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Search for other works by this author on:
Brigitte M. Jockusch,
Brigitte M. Jockusch
bDepartment of Cell Biology, Zoological Institute, Technical University of Braunschweig, 38106 Braunschweig, Germany
Search for other works by this author on:
Siegfried Scherneck
Siegfried Scherneck
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Search for other works by this author on:
Jürgen Janke
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Kathrin Schlüter
bDepartment of Cell Biology, Zoological Institute, Technical University of Braunschweig, 38106 Braunschweig, Germany
Burkhard Jandrig
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Michael Theile
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Konrad Kölble
cInstitute of Pathology, Charité Hospital, Humboldt University, 10117 Berlin, Germany
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Wolfgang Arnold
dHepaVec GmbH, 13125 Berlin-Buch, Germany
Edgar Grinstein
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Arnfried Schwartz
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Lope Estevéz-Schwarz
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Peter M. Schlag
eClinic of Surgery and Surgical Oncology, Robert Roessle Hospital, 13122 Berlin-Buch, Germany
Brigitte M. Jockusch
bDepartment of Cell Biology, Zoological Institute, Technical University of Braunschweig, 38106 Braunschweig, Germany
Siegfried Scherneck
aDepartment of Medical Genetics, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin-Buch, Germany
Abbreviations used in this paper: DTT, dithiothreitol; FBS, fetal bovine serum; PBGD, porphobilinogen deaminase/hydroxymethylbilane synthase; PFN1, profilin 1 gene; RT, reverse transcription.
Received:
October 27 1999
Revision Requested:
February 14 2000
Accepted:
February 23 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 191 (10): 1675–1686.
Article history
Received:
October 27 1999
Revision Requested:
February 14 2000
Accepted:
February 23 2000
Citation
Jürgen Janke, Kathrin Schlüter, Burkhard Jandrig, Michael Theile, Konrad Kölble, Wolfgang Arnold, Edgar Grinstein, Arnfried Schwartz, Lope Estevéz-Schwarz, Peter M. Schlag, Brigitte M. Jockusch, Siegfried Scherneck; Suppression of Tumorigenicity in Breast Cancer Cells by the Microfilament Protein Profilin 1. J Exp Med 15 May 2000; 191 (10): 1675–1686. doi: https://doi.org/10.1084/jem.191.10.1675
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement